Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1754 | 0.7096 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1724 | 0.6887 | 0.9706 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Onchocerca volvulus | 0.1754 | 0.7096 | 0.5 | |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1035 | 0.2023 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1724 | 0.6887 | 0.9706 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1724 | 0.6887 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1035 | 0.2023 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.